ONCS - ONCS STOCK NEWS

OncoSec Medical (NASDAQ: ONCS) announced a corporate restructuring to prioritize the development of its lead candidate, TAVO™ (TAVO-EP), aimed at enhancing its cash runway. The restructuring includes a 45% workforce reduction, focusing efforts on advancing TAVO-EP in the KEYNOTE-695 clinical trial for metastatic melanoma. Top-line results for key endpoints are expected in late 2022 and early 2023. CEO Robert H. Arch emphasized the importance of this move for accelerating TAVO-EP's development while acknowledging the impact on talented employees.

OncoSec Medical announced that its publication in Molecular Cancer Research has been recognized as the Editor's Pick for June 2022. The study discusses the combination of IL-12 and T cell receptor signaling's synergistic effects on anti-tumor immunity. CEO Robert H. Arch highlighted the durable immune responses from intratumoral electroporation of plasmid IL-12 (TAVO™). The research suggests that pairing IL-12 with a polyclonal T cell stimulator enhances T cell activation and reduces suppressive effects of regulatory T cells, indicating potential for future clinical development.

OncoSec Medical (NASDAQ: ONCS) announced it has received the 2022 Vanguard Award from the Triple Negative Breast Cancer (TNBC) Foundation. Kimberly Irvine, Head of Patient Advocacy, will accept the award on May 25, 2022, during the gala "No One Fights Alone." The award recognizes OncoSec's commitment to developing therapies for metastatic TNBC. TAVO™, OncoSec's gene therapy platform, has shown promise in clinical trials for metastatic melanoma and TNBC, receiving Orphan Drug and Fast-Track Designation from the FDA.

OncoSec Medical Incorporated (NASDAQ: ONCS) announced the appointment of Dr. Robert H. Arch as President and CEO, effective April 29, 2022. Dr. Arch brings over 28 years of experience in biopharma, having previously held leadership roles at Elpiscience Biopharma and Novartis. His expertise includes cancer and immuno-oncology, which aligns with OncoSec's focus on developing intratumoral immunotherapies, including its lead candidate TAVO™. As part of his compensation, Dr. Arch received stock options for 700,000 shares, set to vest quarterly, highlighting the company's commitment to aligning leadership with long-term shareholder value.

OncoSec Medical (NASDAQ: ONCS) announced the appointment of George Chi as Chief Financial Officer, effective immediately. Chi brings extensive financial experience, having previously served as CEO of THPlasma and CFO of CASI Pharmaceuticals. His background includes leadership roles in global financial functions across various industries. OncoSec is focused on developing intratumoral immunotherapies, with its lead candidate, TAVO™, showing promise in stimulating immune responses against cancer. The company aims to leverage Chi's experience for future growth.

OncoSec Medical Incorporated (NASDAQ: ONCS) announced significant changes to its Board of Directors. Margaret Dalesandro, Ph.D., has resigned, and Dr. Linda Shi, M.D., Ph.D., has been appointed as the new Chair. Dr. Shi brings over 30 years of experience from various roles, including Chief Medical Officer at Grand Pharma. Additionally, Yuhang Zhao, Ph.D., has also resigned from the Board. The company continues its search for a new CEO, indicating ongoing transitions in leadership.

OncoSec Medical will host a conference call and webcast on November 12, 2021, at 7:00 AM ET to discuss updated data from the KEYNOTE-695 clinical trial, which focuses on metastatic melanoma patients not responding to immune checkpoint blockade. Key opinion leaders, including Dr. Adil Daud from UCSF, will explore the clinical significance of this data presented at the SITC 2021 Annual Meeting. OncoSec's investigational product, TAVO™, aims to enhance immune responses in treating resistant cancer types.

OncoSec Medical (NASDAQ: ONCS) announced that Chief Scientific Officer Chris Twitty will step down to join a private oncology firm. The board expressed gratitude for his leadership over the past five years. The company remains positive about the maturing data from the KEYNOTE-695 study, with top-line results set to be revealed in Q1 2022. TAVO data will be presented at the SITC 2021 meeting on November 12, and updates will also be shared at the SABCS in December. The Leadership Committee is actively searching for a new CEO.

OncoSec Medical Incorporated (NASDAQ:ONCS) announced the formation of a Leadership Committee focused on the development of its lead asset, TAVO™, following the departure of interim CEO Brian Leuthner. The Committee includes Dr. Margaret Dalesandro, Dr. Herbert Kim Lyerly, and Dr. Yuhang Zhao, all with extensive backgrounds in oncology and biotechnology. The search for a permanent CEO is ongoing. TAVO™ aims to stimulate the immune system to attack cancer through localized IL-12 delivery, with ongoing clinical trials demonstrating a promising safety profile and immune response.